| Dr Lynn E Yonge, MD | |
|
405 N Section St, Fairhope, AL 36532-2613 | |
| (251) 990-8860 | |
| (251) 990-3401 |
| Full Name | Dr Lynn E Yonge |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 38 Years |
| Location | 405 N Section St, Fairhope, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235113861 | NPI | - | NPPES |
| 51093217 | Other | AL | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 13517 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Thomas Hospital | Fairhope, AL | Hospital |
| Entity Name | Lynn E. Yonge, M.d., P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710169982 PECOS PAC ID: 2062596596 Enrollment ID: O20080222000277 |
News Archive
Phase Forward, a leading provider of data solutions for clinical trials and drug safety, today announced the availability of version 7.2 of its Empirica™ Signal product, a significant new release of the company's flagship signal detection and management software. The Empirica Signal solution is a state-of-the-art data mining and knowledge management tool and a cornerstone component of Phase Forward's Empirica Suite of pharmacovigilance and risk management products.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has launched www.MuGard.com. The patient- and healthcare professional- focused site is a comprehensive resource offering educational material on oral mucositis, patient analysis, MuGard product and how-to-order information.
On October 1, 2014, all health plans, health data clearinghouses, and health care providers that transmit health information electronically must use a new, significantly broader, coding system, called ICD-10, for diagnoses and inpatient procedures.
The principles of the gene network for colon tumorigenesis have been identified by a KAIST research team. The principles will be used to find the molecular target for effective anti-cancer drugs in the future. Further, this research gained attention for using a systems biology approach, which is an integrated research area of IT and BT.
A team led by a biomedical scientist at the University of California, Riverside, reports a drug - an estrogen receptor ligand called indazole chloride (IndCl) - has the potential to improve vision in patients with multiple sclerosis, or MS.
› Verified 6 days ago
| Entity Name | Veterans Recovery Resources |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285140004 PECOS PAC ID: 4486900446 Enrollment ID: O20180705000227 |
News Archive
Phase Forward, a leading provider of data solutions for clinical trials and drug safety, today announced the availability of version 7.2 of its Empirica™ Signal product, a significant new release of the company's flagship signal detection and management software. The Empirica Signal solution is a state-of-the-art data mining and knowledge management tool and a cornerstone component of Phase Forward's Empirica Suite of pharmacovigilance and risk management products.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has launched www.MuGard.com. The patient- and healthcare professional- focused site is a comprehensive resource offering educational material on oral mucositis, patient analysis, MuGard product and how-to-order information.
On October 1, 2014, all health plans, health data clearinghouses, and health care providers that transmit health information electronically must use a new, significantly broader, coding system, called ICD-10, for diagnoses and inpatient procedures.
The principles of the gene network for colon tumorigenesis have been identified by a KAIST research team. The principles will be used to find the molecular target for effective anti-cancer drugs in the future. Further, this research gained attention for using a systems biology approach, which is an integrated research area of IT and BT.
A team led by a biomedical scientist at the University of California, Riverside, reports a drug - an estrogen receptor ligand called indazole chloride (IndCl) - has the potential to improve vision in patients with multiple sclerosis, or MS.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Lynn E Yonge, MD 405 N Section St, Fairhope, AL 36532-2613 Ph: (251) 990-8860 | Dr Lynn E Yonge, MD 405 N Section St, Fairhope, AL 36532-2613 Ph: (251) 990-8860 |
News Archive
Phase Forward, a leading provider of data solutions for clinical trials and drug safety, today announced the availability of version 7.2 of its Empirica™ Signal product, a significant new release of the company's flagship signal detection and management software. The Empirica Signal solution is a state-of-the-art data mining and knowledge management tool and a cornerstone component of Phase Forward's Empirica Suite of pharmacovigilance and risk management products.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has launched www.MuGard.com. The patient- and healthcare professional- focused site is a comprehensive resource offering educational material on oral mucositis, patient analysis, MuGard product and how-to-order information.
On October 1, 2014, all health plans, health data clearinghouses, and health care providers that transmit health information electronically must use a new, significantly broader, coding system, called ICD-10, for diagnoses and inpatient procedures.
The principles of the gene network for colon tumorigenesis have been identified by a KAIST research team. The principles will be used to find the molecular target for effective anti-cancer drugs in the future. Further, this research gained attention for using a systems biology approach, which is an integrated research area of IT and BT.
A team led by a biomedical scientist at the University of California, Riverside, reports a drug - an estrogen receptor ligand called indazole chloride (IndCl) - has the potential to improve vision in patients with multiple sclerosis, or MS.
› Verified 6 days ago
Dr. Kristin B Kalmbacher, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 100 N Bancroft St, Suite A2, Fairhope, AL 36532 Phone: 251-517-1050 Fax: 251-517-1051 | |
Dr. Rodney Allen Sirk, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 341 Greeno Rd N, Fairhope, AL 36532 Phone: 334-618-2237 | |
Dr. Cameron Townsend Corte, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 8050 Spring Run Dr, Fairhope, AL 36532 Phone: 727-269-6008 | |
Dr. Ashley Dan Coleman, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 188 Hospital Dr, Ste 202, Fairhope, AL 36532 Phone: 251-990-1922 | |
Amanda Woods Robinson, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 21950 State Highway 181 Ste A, Fairhope, AL 36532 Phone: 251-621-6520 Fax: 251-621-6521 | |
Jessica Sheldon, CRNP Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 750 Morphy Ave, Fairhope, AL 36532 Phone: 251-279-1151 | |
Dr. Vaughn H Mancha Jr., MD Family Medicine Medicare: Medicare Enrolled Practice Location: 17326 Burwick Loop, Fairhope, AL 36532 Phone: 334-300-2511 Fax: 334-265-0945 |